Literature DB >> 18680485

Gaining efficiencies: resources and demand for dialysis around the globe.

Nancy Neil1, David R Walker, Ricardo Sesso, Juan Carlos Blackburn, Elizabeth A Tschosik, Vito Sciaraffia, Fernando García-Contreras, Dimitrie Capsa, Samir K Bhattacharyya.   

Abstract

OBJECTIVES: End-stage renal disease (ESRD) is a debilitating condition resulting in death unless treated. Treatment options are transplantation and dialysis. Alternative dialysis modalities are peritoneal dialysis (PD) and hemodialysis (HD), each of which has been shown to produce similar outcomes and survival. Nevertheless, the financial implications of each modality are different and these differences vary by country, especially in the developing world. Changes in clinically appropriate dialysis delivery leading to more efficient use of resources would increase the resources available to treat ESRD or other disabling conditions. This article outlines the relative advantages of HD and PD and uses budget impact analysis to estimate the country-specific, 5-year financial implications on total dialysis costs assuming utilization shifts from HD to PD in two high-income (UK, Singapore), three upper-middle-income (Mexico, Chile, Romania), and three lower-middle-income (Thailand, China, Colombia) countries.
RESULTS: Peritoneal dialysis is a clinically effective dialysis option that can be significantly cost-saving compared to HD, even in developing countries.
CONCLUSIONS: The magnitude of costs associated with treating ESRD patients globally is large and growing. PD is a clinically effective dialysis option that can be used by a majority of ESRD patients and can also be significantly cost-saving compared to HD therapy. Increasing clinically appropriate PD use would substantially reduce health-care costs and help health-care systems meet ever-tightening budget constraints.

Entities:  

Mesh:

Year:  2008        PMID: 18680485     DOI: 10.1111/j.1524-4733.2008.00414.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  18 in total

1.  Global trends in rates of peritoneal dialysis.

Authors:  Arsh K Jain; Peter Blake; Peter Cordy; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 10.121

Review 2.  Economic evaluation of dialysis therapies.

Authors:  Scott W Klarenbach; Marcello Tonelli; Betty Chui; Braden J Manns
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

3.  Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis.

Authors:  Laura Cortés-Sanabria; Brenda E Rodríguez-Arreola; Victor R Ortiz-Juárez; Herman Soto-Molina; Leonardo Pazarín-Villaseñor; Héctor R Martínez-Ramírez; Alfonso M Cueto-Manzano
Journal:  Perit Dial Int       Date:  2013-04-01       Impact factor: 1.756

4.  Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.

Authors:  Hui Zhang; Chao Zhang; Sufen Zhu; Hongjian Ye; Donglan Zhang
Journal:  BMC Health Serv Res       Date:  2020-02-14       Impact factor: 2.655

5.  Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.

Authors:  Frank X Liu; Surrey M Walton; Robert Leipold; Deborah Isbell; Thomas A Golper
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

6.  Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.

Authors:  Erika G Martin; A David Paltiel; Rochelle P Walensky; Bruce R Schackman
Journal:  Value Health       Date:  2010-10-15       Impact factor: 5.725

7.  Report of the first peritoneal dialysis program in Guyana, South America.

Authors:  Maria Altieri; Tarun R Jindal; Mayur Patel; David K Oliver; Edward M Falta; Eric A Elster; Alden Doyle; Stephen R Guy; Arthur L Womble; Rahul M Jindal
Journal:  Perit Dial Int       Date:  2013 Mar-Apr       Impact factor: 1.756

8.  A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil.

Authors:  Mirhelen Mendes de Abreu; David R Walker; Ricardo C Sesso; Marcos B Ferraz
Journal:  Perit Dial Int       Date:  2012-12-03       Impact factor: 1.756

9.  Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

Authors:  Edwin M Spithoven; Anneke Kramer; Esther Meijer; Bjarne Orskov; Christoph Wanner; Jose M Abad; Nuria Aresté; Ramón Alonso de la Torre; Fergus Caskey; Cécile Couchoud; Patrik Finne; James Heaf; Andries Hoitsma; Johan de Meester; Julio Pascual; Maurizio Postorino; Pietro Ravani; Oscar Zurriaga; Kitty J Jager; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

10.  Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.

Authors:  Achuthan Sourianarayanane; Rupesh Raina; Gaurav Garg; Arthur J McCullough; Robert S O'Shea
Journal:  Int Urol Nephrol       Date:  2013-08-10       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.